Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GSR | P00390 | 2/20 | 0.80 |
| ▸ | ARG2 | P78540 | 4/20 | 0.70 |
| ▸ | ARG1 | P05089 | 3/20 | 0.70 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.62 |
| ▸ | GRM8 | O00222 | 1/20 | 0.62 |
| ▸ | GRM6 | O15303 | 1/20 | 0.62 |
| ▸ | GRIN2D | O15399 | 1/20 | 0.62 |
| ▸ | GRIN3B | O60391 | 1/20 | 0.62 |
| ▸ | GRIK1 | P39086 | 1/20 | 0.62 |
| ▸ | GRM5 | P41594 | 1/20 | 0.62 |
| ▸ | GRIA1 | P42261 | 1/20 | 0.62 |
| ▸ | GRIA2 | P42262 | 1/20 | 0.62 |
| ▸ | GRIA3 | P42263 | 1/20 | 0.62 |
| ▸ | SLC1A3 | P43003 | 1/20 | 0.62 |
| ▸ | SLC1A2 | P43004 | 1/20 | 0.62 |
| ▸ | SLC1A1 | P43005 | 1/20 | 0.62 |
| ▸ | GRIA4 | P48058 | 1/20 | 0.62 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.62 |
| ▸ | GRIN2A | Q12879 | 1/20 | 0.62 |
| ▸ | GRIK2 | Q13002 | 1/20 | 0.62 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29268443 | 1.00 | GSR (0.80) | GSRARG2ARG1CYP1A2GRM8 | |
| SCHEMBL293201 | 1.00 | GSR (0.80) | GSRARG2ARG1CYP1A2GRM8 | |
| SCHEMBL21689907 | 1.00 | GSR (0.80) | GSRARG2ARG1CYP1A2GRM8 | |
| SCHEMBL8893420 | 0.97 | GSR (0.76) | GSRARG2ARG1CYP1A2GRM8 | |
| Hydrochloric Acid SCHEMBL20541044 | 0.97 | GSR (0.76) | GSRARG2ARG1CYP1A2GRM8 | |
| SCHEMBL8894128 | 0.97 | GSR (0.76) | GSRARG2ARG1CYP1A2GRM8 | |
| Hydrochloric Acid SCHEMBL20541045 | 0.97 | GSR (0.76) | GSRARG2ARG1CYP1A2GRM8 | |
| Hydrochloric Acid SCHEMBL20541043 | 0.97 | GSR (0.76) | GSRARG2ARG1CYP1A2GRM8 | |
| SCHEMBL6741106 | 0.97 | GSR (0.76) | GSRARG2ARG1CYP1A2GRM8 | |
| SCHEMBL9829771 | 0.97 | GSR (0.76) | GSRARG2ARG1CYP1A2GRM8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 31 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260085103-A1 | LONG-ACTING INSULIN COMPOUND | CHENGDU AODA BIOTECHNOLOGY CO LTD (CN) | 2026-03-26 | — | — | US | disclosed |
| EP-4570820-A1 | LONG-ACTING INSULIN COMPOUND | Chengdu Aoda Biotechnology Co., Ltd. (CN) | 2025-06-18 | — | — | EP | disclosed |
| US-10759748-B2 | Compounds as L-cystine crystallization inhibitors and uses thereof | NEW YORK UNIVERSITY (US) | 2020-09-01 | — | — | US | disclosed |
| EP-1984384-B1 | Conotoxin analogues, and methods for synthesis of intramolecular dicarba bridge containing peptides | SYNGENE LTD (AU) | 2015-10-21 | — | — | EP | disclosed |
| US-20150099806-A1 | COMPOUNDS AS L-CYSTINE CRYSTALLIZATION INHIBITORS AND USES THEREOF | NEW YORK UNIVERSITY | 2015-04-09 | — | — | US | disclosed |
| US-20150099806-A1 | COMPOUNDS AS L-CYSTINE CRYSTALLIZATION INHIBITORS AND USES THEREOF | NEW YORK UNIVERSITY | 2015-04-09 | — | — | US | disclosed |
| US-8916609-B2 | Compounds as L-cystine crystallization inhibitors and uses thereof | NEW YORK UNIVERSITY (US) | 2014-12-23 | — | — | US | disclosed |
| US-8916609-B2 | Compounds as L-cystine crystallization inhibitors and uses thereof | NEW YORK UNIVERSITY (US) | 2014-12-23 | — | — | US | disclosed |
| US-8759480-B2 | Contoxin analogues and methods for synthesis of intramolecular dicarba bridge-containing peptides | SYNGENE LIMITED (AU) | 2014-06-24 | — | — | US | disclosed |
| US-8748570-B2 | Insulin analogues | SYNGENE LIMITED (AU) | 2014-06-10 | — | — | US | disclosed |
| WO-2011146974-A1 | METHODS FOR THE SYNTHESIS OF ALKYNE-CONTAINING DICARBA BRIDGES IN PEPTIDES | MONASH UNIVERSITY (AU) | 2011-12-01 | — | — | WO | disclosed |
| WO-2011146973-A1 | INSULIN ANALOGUES | MONASH UNIVERSITY (AU) | 2011-12-01 | — | — | WO | disclosed |
| US-7745573-B2 | Conotoxin analogues and methods for synthesis of intramolecular dicarba bridge-containing peptides | POLYCHIP PHARMACEUTICALS PTY LTD. (AU) | 2010-06-29 | — | — | US | disclosed |
| US-20100036089-A1 | Methods for the Synthesis of Dicarba Bridges in Organic Compounds | MONASH UNIVERSITY (AU) | 2010-02-11 | — | — | US | disclosed |
| US-20100022749-A1 | Contoxin Analogues and Methods for Synthesizing Same | MONASH UNIVERSITY (AU) | 2010-01-28 | — | — | US | disclosed |
| EP-1984385-A1 | METHODS FOR THE SYNTHESIS OF DICARBA BRIDGES IN ORGANIC COMPOUNDS | MONASH UNIVERSITY (AU) | 2008-10-29 | — | — | EP | disclosed |
| EP-1984386-A1 | METHODS FOR THE SYNTHESIS OF TWO OR MORE DICARBA BRIDGES IN ORGANIC COMPOUNDS | Monash University (AU) | 2008-10-29 | — | — | EP | disclosed |
| WO-2007093014-A1 | METHODS FOR THE SYNTHESIS OF TWO OR MORE DICARBA BRIDGES IN ORGANIC COMPOUNDS | MONASH UNIVERSITY (AU) | 2007-08-23 | — | — | WO | disclosed |
| WO-2007093013-A1 | METHODS FOR THE SYNTHESIS OF DICARBA BRIDGES IN ORGANIC COMPOUNDS | MONASH UNIVERSITY (AU) | 2007-08-23 | — | — | WO | disclosed |
| US-20070197429-A1 | Conotoxin analogues and methods for synthesis of intramolecular dicarba bridge-containing peptides | SYNGENE LIMITED (AU) | 2007-08-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150099806-A1 | COMPOUNDS AS L-CYSTINE CRYSTALLIZATION INHIBITORS AND USES THEREOF | ATP6V1B1, GLS, REN | GSR 514/4885ARG2 445/4885ARG1 344/4885 |
| US-20100022749-A1 | Contoxin Analogues and Methods for Synthesizing Same | VIP, CANX, PDIA5 | GSR 2716/4885ARG2 2876/4885ARG1 3154/4885 |
| US-20260085103-A1 | LONG-ACTING INSULIN COMPOUND | IAPP, INSR, IDE | GSR 2547/4885ARG2 76/4885ARG1 36/4885 |
| US-20100036089-A1 | Methods for the Synthesis of Dicarba Bridges in Organic Compounds | DCLRE1A, RNF168, MTCL3 | GSR 1784/4885ARG2 2699/4885ARG1 3698/4885 |
| US-10759748-B2 | Compounds as L-cystine crystallization inhibitors and uses thereof | ATP6V1B1, GLS, REN | GSR 514/4885ARG2 445/4885ARG1 344/4885 |
| US-20070197429-A1 | Conotoxin analogues and methods for synthesis of intramolecular dicarba bridge-containing peptides | VIP, NRDC, INHA | GSR 3939/4885ARG2 3130/4885ARG1 2732/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.